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Chemical modification of epibatidine causes a switch from
agonist to antagonist and modifies its selectivity for neuronal
nicotinic acetylcholine receptors
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Background: Studies of ligand gated channels strongly rely on the availability
of compounds that can activate or inhibit with high selectivity one set or a
subset of defined receptors. The alkaloid epibatidine (EPB), originally isolated
from the skin of an Ecuadorian poison frog, is a very specific agonist for the
neuronal nicotinic acetylcholine receptors (nAChRs). We used EPB derivatives
to investigate the pharmacophore of nAChR subtypes.
Results: Optically pure enantiomers of EPB analogues were synthesised.
Analogues were obtained altered in the aromatic part: the chlorine was
eliminated and the relative position of the pyridyl nitrogen changed. Voltage
clamp electrophysiology was performed with these compounds on neuronal
nAChRs reconstituted in Xenopus oocytes. The EPB derivatives show different
activities towards the various nAChR subtypes.
Conclusions: Small changes in the molecular structure of EPB produce
marked changes in its capacity to activate the nAChRs. Subtype specificity can
be obtained by changing the position of or by eliminating the pyridyl nitrogen.
Introduction
Studies of ligand-gated channels strongly rely on the avail-
ability of compounds that can activate or inhibit with high
selectivity one set or subset of receptors. For example,
natural toxins, such as the snake toxin α-bungarotoxin,
have largely been employed to characterise the nicotinic
acetylcholine receptor (nAChR). Although very specific,
these polypeptide toxins are difficult to synthesise and
modify. Simpler molecules that can be made using organic
chemistry methods are therefore required to study struc-
ture–activity relationships. The alkaloid epibatidine
(EPB), originally isolated from the skin of the Ecuadorian
poison frog Epibetobates tricolor [1–3], is a very specific
agonist of the neuronal nAChR (reviewed in [4,5]).This
opened new ways to investigate the properties of the phar-
macophore of these receptors. This molecule can be syn-
thesised (reviewed in [6–8]) and several of its derivatives
and analogues have already been investigated using bio-
chemical and electrophysiological approaches [9–17].
Both enantiomers of EPB ((+) and (–)) exhibit amongst
the highest known affinities towards the central brain
nAChR α4β2 (0.045 and 0.058 nM, respectively) [18] as
well as towards the homomeric nAChR α7 (16 nM) [19].
Functional studies have shown that EPB is one of the
most potent activators of the α4β2 receptors (EC50 16 nM)
but that it is a weak agonist at the homomeric α7 nAChR
with an EC50 value in the micromolar range [20–22]. The
nAChR sensitivity to EPB is influenced by small struc-
tural modifications [17,22–24]. EPB is one of the most
toxic natural compounds [10,25,26]. The toxicity of EPB
may arise from its capacity to activate both the central
neuronal α4β2 and the ganglionic α3β4 nAChR. 
The structural requirements that define an agonist versus
an antagonist are poorly understood. In one of the pharma-
cophore models it has been proposed that a nicotinic
agonist requires a charged nitrogen and a hydrogen bond
acceptor at distances of 5.9 Å [27] or 4.4–5.0 Å [28].
According to a re-interpretation of this model [29], the
ideal distance between these two groups would be 5.5 Å,
the intramolecular nitrogen–nitrogen distance in EPB.
Limitations of this model are evident when considering
the different compounds acting at the nAChR. For
example, tetramethyl ammonium chloride, which is a
potent agonist at α4β2 and α7 receptors, does not fulfil
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this ‘pharmacophore model’ requirement. Furthermore,
tetramethyl ammonium derivatives choline and ethyl-
trimethyl ammonium show a strong selectivity in activat-
ing the α7 subtype [30–33]. 
This model is based only on affinity data obtained in
binding measurements and does not take into account the
efficacy of the different compounds in eliciting a func-
tional response. We have therefore synthesised EPB
derivatives and examined their functional properties on
nAChRs reconstituted in Xenopus oocytes. Because we
have recently shown a significant enantioselectivity in
N-methylated derivatives of EPB [22,34], we used mainly
optically pure substances.
We examined the role of the pyridine nitrogen as the
hydrogen-bond acceptor in receptor activation and binding.
We simplified the EPB structure by eliminating the chlo-
rine atom to generate dechloroepibatidine (DClEPB).
Then we switched the pyridine nitrogen from the meta to
the ortho or para position to yield exo-2-(2-pyridyl)-7-azabi-
cyclo[2.2.1]heptane (2PABH) and exo-2-(4-pyridyl)-7-azabi-
cyclo[2.2.1]heptane (4PABH), respectively. Finally the
hydrogen-bond acceptor was fully removed to give exo-2-
phenyl-7-azabicyclo[2.2.1]heptane (PABH).
We also examined the influence of the [2.2.1]azabicyclo
moiety by comparing with homoepibatidine (HEPB, exo-
6-(2-chloro-5-pyridyl)-8-azabicyclo-[3.2.1]octane). Results
obtained with this approach can be interpreted on the
basis of a model in which the EPB binds at the interface
between two adjacent subunits. In addition, we illustrate
that the properties of EPB derivatives compared with
those of EPB itself can be explained using an allosteric
model of the nAChRs.
Results 
Activity of DClEPB
The electrophysiological experiments with DClEPB
enantiomers on the major brain nAChR α4β2 and gan-
glionic α3β4 are illustrated in Figure 1. Typical currents
evoked by ACh and the two DClEPB enantiomers in an
α4β2 responsive oocyte are illustrated in the left panel of
Figure 1a. The response time course of either enan-
tiomer showed no significant difference compared with
that of ACh. Mean dose-response curves (n = 4) mea-
sured over a broad concentration range of the two enan-
tiomers are shown in the right panel. Data are
represented as a fraction of the current evoked by a satu-
rating ACh concentration (1 mM). 
The efficacy — the ratio of the current evoked at satura-
tion for a given agonist over the current evoked by the
natural agonist ACh — is different for the two DClEPB
enantiomers. The (+)-form displays a higher affinity and
higher efficacy. In contrast, the α4β2 nAChR exhibits
a lower sensitivity to the (–)-DClEPB and also a lower
efficacy of 80%.
Comparison of the EC50 values measured for (+)- and (–)-
DClEPB with those of the (+)- and (–)-EPB shows that, in
contrast to results obtained in binding experiments [9,18],
removal of the chlorine atom markedly modifies the α4β2
sensitivity to EPB and causes a shift in efficiency of
40–100-fold together with a modification of the efficacy
(see Table 1).
The sensitivity of the ganglionic α3β4 nAChR to the
DClEPB enantiomers was analysed as described above.
Both enantiomers induced strong currents, the time courses
of which could not be distinguished from each other, indi-
cating the absence of enantiomeric selectivity (see left
panel Figure 1b). Dose-response measurements (n = 4) also
revealed no major differences between the two DClEPB
enantiomers (right panel Figure 1b). On average, the sensi-
tivity of the ganglionic α3β4 subtype was an order of mag-
nitude higher than that of the α4β2 nAChR (Table 1). 
As expected from previous studies, oocytes expressing the
homomeric α7 nAChR responded to ACh with very fast
desensitising currents [35–38]. Typical α7 currents
evoked by ACh and the two DClEPB enantiomers are
shown in Figure 1c. In comparison with ACh responses,
the amplitude of the currents evoked by both DClEPB
enantiomers were slightly higher, suggesting a stronger
efficacy (Table 1). As with the ganglionic receptor, no
enantiomeric selectivity was detected in efficacy or in effi-
ciency. Moreover, also in agreement with previous find-
ings obtained with EPB [20] cited by [4], [21] cited by [5],
[22] the α7 subtype displayed the weakest sensitivity
towards DClEPB, just below that of the α4β2 nAChR
(n = 4, see Table 1).
Activity of 2PABH
2PABH was the first compound in a series of modifica-
tions, which allowed us to investigate the role of the
hydrogen-bond acceptor for receptor recognition and acti-
vation. The pyridine nitrogen in 2PABH was not in the
meta position but in the ortho position with respect to the
bicyclo moiety. This results in a decreased intramolecular
N–N distance and in a changed spatial orientation of the
pyridine nitrogen (Figure 2). The N–N distance calcu-
lated for EPB and DClEPB varies between 4.4 and 5.8 Å,
as estimated by CS Chem3D Pro (CambridgeSoft)
depending on the rotation around the C–C bond between
the two ring systems. Accepting 5.5 Å as the optimal N–N
distance for DClEPB [29] and keeping the same rotational
orientation the N–N distance in 2PABH was 4.4 Å after
energy minimisation.
Preliminary studies have been reported recently showing
that a 30 µM concentration of either of the two 2PABH
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enantiomers evoked no detectable response at α4β2 or
α3β4 receptors. At the α7 nAChR, only the (–)-enan-
tiomer was a partial agonist with ~80% of the ACh
response and an EC50 value of 32.5 ± 9.5 µM [24]. In
comparison with DClEPB this is a dramatic change in the
agonist profile. Dose-response curves were measured
over a broad range of (+)- and (–)-2PABH concentrations
(up to 300 µM) to see if 2PABH behaves as a partial
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Figure 1
Elimination of the chlorine at the 4′-position of
the 3′-pyridyl group modifies the EPB affinity
considerably. (a) Left, typical currents evoked
by a saturating ACh test pulse at the α4β2
nAChR are compared to (+)-DClEPB and (–)-
DClEPB. Dose-response profiles determined
over a broad range of DClEPB are shown on
the right. Data were normalised with respect
to the ACh evoked current recorded at
saturation (1 mM). Note that a 1.2 coefficient
was used in the curve fitting of (–)-DClEPB
whereas a scaling factor of 0.7 was applied to
(–)-DClEPB. (b,c) Data obtained as in (a) for
(+)-DClEPB and (–)-DClEPB at the
ganglionic α3β4 nAChR and the homomeric
α7 receptor. EC50 values and Hill coefficients
are indicated in Table 1.
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agonist. Preapplication (10 s) of the compound inhibits
the current evoked by a subsequent ACh test pulse
(Figure 3a) showing that this compound binds to the
nAChR recognition site. The small current evoked by the
highest concentration of 2PABH illustrates that this com-
pound may be a partial agonist at the α4β2 nAChRs with
less than 10% efficacy. Moreover, this compound displays
little enantiomeric selectivity for this receptor subtype
(Figure 3a,b and Table 1).
The ganglionic α3β4 receptors did not show a significant
sensitivity towards both 2PABH enantiomers [24]. Prepulse
experiments similar to those described above were per-
formed with this system (Figures 3c,d). When the 2PABH
concentration was raised to 100 µM a significant inward
current was observed. Furthermore, the 2PABH prepulse
yielded no marked inhibition of the subsequent ACh-
evoked current indicating that this compound behaves as
an agonist at the ganglionic receptor subtype. However,
given the low sensitivity of this receptor to 2PABH and the
limited availability of the ligand, it was not possible to
reach a saturating concentration. Extrapolation of the data
indicates that the 2PABH EC50 value must be in the range
of 210 to 740 µM for the (+)- and (–)-enantiomers
(Figures 3c,d and Table 1) and that this receptor does not
markedly distinguish between the two enantiomers.
Further investigation of 2PABH on the α7 receptor con-
firmed and extended the results previously obtained with
this compound [24]. Exposure to (+)-2PABH evoked only
very little current (less than 10% of ACh), whereas
(–)-2PABH behaves as a whole agonist on this receptor
subtype (Figure 3e,f). Coapplication of (+)-2PABH on top
of a fixed ACh concentration provoked a decrease in the
plateau current, indicating that this compound blocks α7
receptor. Determination of the dose-response inhibition
on the plateau phase (Figure 3f) yielded an IC50 value of
48 ± 6 µM and a Hill coefficient of 1 (n = 3). Note the
shortening of the peak duration concomitant to the reduc-
tion of the plateau level (Figure 3e, lower traces).
Activity of 4PABH and PABH
In 4PABH the pyridyl nitrogen was turned to the para
position, which increased the intramolecular N–N distance
548 Chemistry & Biology 2000, Vol 7 No 7
Table 1
Electrophysiological data of EPB and EPB analogues.
µM
α4 β2 α3 β4 α7
(+)-EPB* 0.021 ± 0.005 0.036 ± 0.013 2.5 ± 0.16
1.24 ± 0.1 1.52 ± 0.4 1.45 ± 0.1
(100) (100) (60)
(–)-EPB* 0.023 ± 0.007 0.019 ± 0.006 2.03 ± 0.5
1.30 ± 0.1 1.67 ± 0.2 1.43 ± 0.1
(100) (100) (90)
(+)-DClEPB 0.93 ± 0.2 0.51 ± 0.2 5.25 ± 0.4
0.98 ± 0.06 1 ± 0.025 1.15 ± 0.02
(120) (100) (110)
(–)-DClEPB 2.8 ± 1.1 0.25 ± 0.08 4.6 ± 0.14
0.98 ± 0.1 1.25 ± 0.14 1
(80) (100) (110)
(+)-2PABH 32 ± 8† 207 ± 37 48 ± 6†
1.1 ± 0.03 1.2 ± 0.06 1 ± 0.06
84 ± 9
2.5 ± 0.08
(–)-2PABH 67.5 ± 16† 738 ± 137 32.5 ± 9.5‡
0.925 ± 0.08 1.1 ± 0.07 1.40 ± 0.2
(100)
4PABH {21 ± 6} (100) {0.5 ± 0.06}
PABH {15 ± 5} (100) {1.6 ± 0.06}
(+)-HEPB 0.02 0.02
1.1 1.4
(100) (100)
(–)-HEPB > 1 0.6 / 1.6
EC50 ± SEM, Hill coefficients nH ± SEM and (efficacy in % of ACh efficacy); *data taken from [15]; †IC50 ± SEM, Hill coefficients nH ± SEM;
{response of a 300 mM solution in % ACh efficacy}; ‡data taken from [53]. 
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to 5.6 Å (pretty much independent of the rotational posi-
tion around the C–C bond between the ring systems) and
changed the orientation of the hydrogen-bond acceptor
pyridine nitrogen. Elimination of the nitrogen resulted in
PABH. Because of low yields and unsatisfactory enan-
tiomer separation so far only partial (but nevertheless clear)
results could be obtained with these two compounds. 
The current evoked by a 300 µM application of these
ligands was compared to those evoked by saturating ACh
concentrations. Data obtained for the three types of
nAChRs are shown in Figure 4 and Table 1. Currents
recorded in an oocyte expressing α4β2 (Figure 4a) illus-
trate that this receptor has little sensitivity to either
4PABH or PABH. In contrast, with the ganglionic recep-
tor, a significant inward current resembling that evoked by
ACh was recorded (Figure 4b). These results indicate that
the nitrogen of the pyridine ring is not indispensable for
the activation of the α3β4 receptor. Although modification
of the N–N distance and the orientation of the hydrogen-
bond acceptor (pyridyl nitrogen) produces little effect on
the ganglionic receptor, a marked difference is observed
for the homomeric α7 nAChR. As shown in Figure 4c, this
receptor displays almost no detectable current even in
response to high concentrations of these two compounds.
Observation of the traces at higher magnification shows,
however, that although 4PABH evokes only a very tran-
sient response, PABH evokes first a sharp peak of current
that is followed by a second and more shallow deflection.
This rebound is reminiscent of open channel blocker
effects [39–42], which suggests that PABH partial agonist
activity may be impaired by an additional blocking effect
that could partly mask the evoked current.
Activity of HEPB
The effect of the azabicyclo moiety on receptor recogni-
tion was assessed by the synthesis of HEPB (Figure 2).
The enlargement of the rigid [2.2.1]- to a [3.2.1]-cage
induced some flexibility and extended the bulky bicyclo
structure into the direction opposite the pyridine ring with
some change in pyridine nitrogen (hydrogen-bond accep-
tor) orientation and N–N distance (6.2 Å) in the free mol-
ecule. This is a consequence of the change in rotational
position around the ‘ring-systems-connecting’ C–C bond
upon energy minimisation. If the C–C bond is rotated
back to the EPB position, the pyridine nitrogen (hydro-
gen-bond acceptor) orientation and N–N distance is the
same as for EPB (5.5 Å).
Typical currents evoked at the α4β2 nAChR by different
concentrations of HEPB enantiomers are illustrated in
Figure 5a. Responses to ACh and (+)-HEPB were com-
parable, showing that this compound acts as a full
agonist. The efficiency is comparable to that of EPB
(Table 1). A marked difference is observed, however,
when comparing currents recorded in the same cell in
response to (–)-HEPB. Both the amplitude and sensitiv-
ity are affected (right panel Figure 5a, Table 1).
Although the α4β2 indifferently recognises the two EPB
enantiomers, it strongly favours the (+)-conformation of
the HEPB modification.
Figure 5b illustrates the responses of the α3β4 receptor to
ACh and (+)-HEPB, (–)-HEPB for three increasing con-
centrations. ACh and (+)-HEPB evoke comparable cur-
rents but a small difference is observed for the
(–)-enantiomer. Estimation of the half activation value
yielded no significant difference with that of EPB itself
(Table 1). (–)-HEPB exhibited a significantly lower activ-
ity but no less so than observed for α4β2.
Figure 5c illustrates the typical α7 evoked current
obtained in response to ACh, (+)-HEPB and (–)-HEPB.
They evoke currents of roughly the same amplitude, but
(–)-HEPB is at least 100-fold less efficacious. Because of
the limited amount of material available, saturation could
not be assessed in any of the cells tested. 
Discussion
In this work we have examined the structure–activity rela-
tionship of the agonist EPB and its non-natural derivatives
on neuronal nAChRs reconstituted in Xenopus oocytes.
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Figure 2
The EPB analogues. The structure of EPB was modified in two ways.
(a) Stepwise modifications of the pyridine ring led to a series of
analogues shown on the right. (b) The enlargement of the aza-bicyclo
moiety resulted in the homologue displayed on the left. Note that the
absolute configuration of the structures is only known for EPB.
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The convergent character of the synthetic approach
offered the possibility of coupling different aromatic
groups to different bicycloheptenes. The EPB structure
could, therefore, easily be varied and a broad range of EPB
analogues (HEPB, DClEPB, 2PABH, 4PABH and PABH)
were accessible (Figure 2).
The ligand-binding site of the nAChRs lies at the inter-
face between two adjacent subunits [43–46]. The nicotinic
pharmacophore for an effective agonist requires a charged
nitrogen and a hydrogen-bond acceptor group [27,28,47].
The binding pocket possesses one area to recognise the
positive charge and a second one to form a hydrogen bond
with the pyridine nitrogen.
By alignment of sequences of α subunits [45,48] and by
point mutations in the complementary component [49]
the model of the binding site shown in Figure 6 was for-
mulated [49,50]. The amino acids Tyr93, Trp149, Tyr151,
Tyr190 and Tyr198 were shown by photoaffinity labelling
550 Chemistry & Biology 2000, Vol 7 No 7
Figure 3
Agonist and antagonistic effects of 2PABH at
the neuronal nAChRs. (a) Effects of pre- and
coapplication of (+)- and (–)-2PABH on the
ACh-evoked current (left panel). Dashed lines
illustrate the timing of the 2PABH applications
and bars indicate the ACh test pulses.
(b) Percentage of inhibition caused by
2PABH pre- and coapplication are plotted as
a function of the 2PABH concentration.
Values were measured during the plateau
phase of the ACh pulse. (c) Effects of 2PABH
at the α3β4 nAChR. Left panel illustrates that
both (+)- and (–)-2PABH are agonists at this
receptor subtype and cause no inhibition of
the subsequent ACh evoked current. (d) ACh,
(+)-and (–)-2PABH dose-response
relationships. Currents evoked by ACh and
one of the 2PABH enantiomers were
determined in the same cells (n = 3 and 5 for
the (+)- and (–)-2PABH). Lines through the
data points are the best fit obtained with the
Hill equation. (e) Typical currents recorded in
response to ACh, (+)-2PABH alone or during
coapplication of these two drugs in an α7
expressing oocyte are illustrated in the left
panel. Note the difference in scale for ACh
and (+)-2PABH. (f) The upper panel
illustrates the agonistic effect of (+)-2PABH
versus ACh. The continuous line through the
2PABH data corresponds to a Hill equation
with a scaling factor of 0.15. The dashed line
corresponds to a Hill equation in which the
EC50 was shifted to 1525 µM. Lower panel
was obtained by plotting the fraction of
plateau current (measured after 3s) as a
function of the (+)-2PABH concentration. IC50
and EC50 values and Hill coefficients are
summarised in Table 1.
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to be part of the binding site in the α subunit in Torpedo
marmorata [51–53]. We have identified these same amino
acids (Tyr92, Trp148, Tyr150, Tyr187 and Tyr194) in the
principal component of the rat α2, α3 and α7 subunits.
These aromatic amino acids interact by cation–pi inter-
action with the positive charge on the quaternary nitrogen,
which is the essential feature for an nAChR-binding site
[33]. The complementary component presents the ligands
with a lipophilic backbone. The loops depicted in
Figure 6 are also found in the ribbon diagram of a calcu-
lated molecular model of the receptor [48].
The first step in a series of modifications on the EPB struc-
ture was the elimination of the chlorine at the 4′-position of
the 3′-pyridyl group (DClEPB, Figure 2). On the one
hand, this structural modification specifically addresses the
role of the halogen in the nAChRs activation. On the other
hand, this modification simplifies the structure and allows
the function of the hydrogen-bond acceptor (pyridyl nitro-
gen) at three different aromatic positions to be evaluated
without further consideration of the relative positions of
the nitrogen and the halogen. In comparison with the
parent compound EPB, both DClEPB enantiomers dis-
played a loss in activity at the heteromeric α4β2 receptor.
As summarised in Table 1 the (–)-enantiomer exhibits a
120-fold reduction in efficiency whereas the (+)-enan-
tiomer is only reduced by about 40-fold. A similar tendency
was shown at the ganglionic α3β4 nAChR. The least pro-
nounced effects were seen with the homomeric α7 recep-
tors which showed a reduction of about half in their
sensitivity to DClEPB versus EPB. The chlorine is there-
fore important for the activation of the heteromeric
nAChRs. In contrast, binding studies with EPB and
DClEPB on rat brain homogenates have revealed that the
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Figure 5
Sensitivity of neuronal nAChRs to (+)- and (–)-HEPB. (a–c) illustrate
recordings obtained for three increasing ACh and HEPB
concentrations at the α4β2, α3β4 and α7 receptors. Cells were
challenged first with ACh and then either with the (+)- or
(–)-enantiomers. In every case, ACh evoked currents were measured at
the end of the test pulse series to verify the absence of blockade or
desensitisation of the receptors.
Figure 4
4PABH and PABH are weak agonists of the neuronal nAChRs. Effects
of 300 µM test pulses of the racemic mixture of 4PABH and PABH are
compared to currents evoked by saturating ACh (1 mM).
(a–c) correspond to the α4β2, α3β4 and α7 receptors, respectively.
To illustrate the very weak agonist effects, data obtained for the α7
receptor are plotted on two different scales. Cells were challenged
once every 2 min; full recovery of the ACh evoked current was always
observed after the washing period. Similar recordings were obtained in
at least three cells for each of the conditions. Bars indicate the timing
of the applications.
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dechloro analogue possessed a slightly increased affinity
[9,18]. These two seemingly different results can be
understood because the two experimental approaches
address a different state of the receptor. We looked into
the capacity of a compound to activate the receptor while
binding measurements cover a longer time and mostly
involve a nonactive state.
The nAChR properties can be taken into account using a
four-state allosteric scheme derived from the original
proposition of Monod, Wyman and Changeux and co-
workers [43,54–59]. According to that model the receptor
is in equilibrium between conformational states. These
discrete conformational states are the inactive basal (B),
active (open) (A), intermediate (I) and inactive desensi-
tised (D) states [43]. The presence of a ligand preferen-
tially stabilises one or more states. Agonists can be stabilise
the A (open) state as compared to the B state, whereas
competitive inhibitors and antagonists are assumed to sta-
bilise the B (closed) or D (closed) states. According to this
model, the efficacy of a given compound reflects its capac-
ity to preferentially stabilise the A state, whereas partial
agonists that are less efficacious must stabilise both the
active as well as a closed state. Affinity measurements
reflect the binding on the receptor at equilibrium.
In the case of DClEPB, it follows that the (+)-enantiomer
preferentially stabilises the A state of α4β2 even better
than ACh, whereas the (–)-enantiomer must stabilise both
the A and to a lesser extent the D and/or B states. The loss
of agonist efficacy between these compounds and EPB
reflects a reduction in stabilisation of the A state. The
para chlorine in EPB obviously enhances the activation of
the A state. As there is no difference in the N–N distance
with or without chlorine, the chlorine enhances the activa-
tion of the A state by optimising the hydrogen bond with
the receptor.
The subsequent EPB derivative was 2PABH. Switching
the pyridine nitrogen from the meta to the ortho position
with respect to the bicyclo ring caused a very marked dif-
ference in the ability of this compound to activate the
receptors. When considering the α4β2 nAChR alone, this
modification completely abolishes the ability of this deriv-
ative to activate the nAChR. The inhibition of the ACh
evoked current observed in the prepulse experiments
(Figure 3) reveals that this compound still binds to the
receptor but now preferentially stabilises a closed state.
2PABH evokes a current at the α3β4 nAChR even if its
efficacy is diminished by more than two orders of magni-
tude. Obviously, the hydrogen-bond acceptor in EPB and
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Figure 6
Model of the binding sites on the nAChR.
Top: The ligand binding site is located at the
interface between an α and the adjacent
subunit. According to the multiple loop model
four loops are involved in the ligand binding.
The amino acids of loop A–D which have been
localised in the binding site by affinity labelling
are represented in black (for reviews see
[40,45,52]). An additional loop has been
identified as a calcium binding site by mutation
of residues Glu161, Asp163, Ser167, Ser169
and Glu172 [49]. The ligand EPB is positioned
into the gap; both nitrogen atoms are shown in
blue, the chlorine in green According to the
nicotinic pharmacophore a ligand possesses at
least a charged nitrogen and a hydrogen bond
acceptor. The aromatic amino acids at position
Trp85, Tyr92, Trp148, Tyr150, Tyr187 and
Tyr194 (shown in red) represent possible
positions to interact by cation-pi interaction with
the charged azabiciyclo-nitrogen of EPB.
Bottom: Sequence alignments of the principal
component (rat α4, α3 and β7 nAChR
sequences) in the region of loops A, B and C
and of the complimentary component (rat β2,
β4 and α7 sequences) in the region of loop D
(sequences taken from the NCBI Genbank).
The loops contain conserved canonical
residues which are indicated by grey
background. The amino acids that are identified
in the binding pocket by affinity labelling (see
above) are shown in bold letters.
8 4 - - - - - - - - - - - - - - - - - 9 9 1 4 3 - - - - - - - - - - - - 1 5 7 1 8 7 - - - - - - 1 9 6 
D loop C loop B loop A loop 
5 0 - - - - - - - - - 5 7 
a 4-rat I W R P D I V L Y N N A D G D F M K F G S W T Y D K A K I D L Y E C C A E I Y P D T T N V W L T Q b 2-rat
a 3-rat I W R P D I V L Y N N A D G D F M K F G S W T Y D K A K I D L Y N C C E E I Y Q D T T S I W L K Q b 4-rat
a 7-rat I W K P D I L L Y N S A D E R F L K F G S W T Y G G W S L D L Y E C C K E P Y P D T T N I W L Q M a 7-rat
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DClEPB must be involved in binding and plays a key role
in stabilising the A state in α3β4.
In contrast to DClEPB, not both enantiomers of 2PABH
could stabilise the A state of the α7 nAChR but only the
(–)-conformation. (+)-2PABH stabilised the B or D state
and when coapplied thus inhibited the ACh response.
Obviously the enantiomers of 2PABH bind to the receptor
differently from those of DClEPB, due to the shorter
N–N distance and the different orientation of the hydro-
gen bonding pyridyl nitrogen.
The small agonist effect of (+)-2PABH (Figure 3f) can be
interpreted either as reflecting the low partial agonist effect
of this compound or the strongly reduced sensitivity of the
α7 receptor. The continuous line through the data points
(filled squares) corresponds to the fit obtained with a Hill
equation assuming a saturating value of 15% of the ACh
current. The dashed line was drawn as an extrapolated dose
response in which the EC
50
value was shifted from 165 to
1525 µM. The fast time course of the response evoked by
300 µM (+)-2PABH (right upper traces Figure 3e) suggests
that this compound behaves as a partial agonist.
The preliminary results obtained for PABH revealed that
removal of the hydrogen-bond acceptor resulted in a com-
pound discriminating for the ganglionic α3β4 nAChR
subtype. Comparison with 2PABH suggests that the pyri-
dine nitrogen of 2PABH is not involved in stabilisation of
the A state at the α3β4 receptor. These results also indi-
cate that the ortho nitrogen plays a key role in activating
the α7 subtype. Comparison of the electrophysiological
profile of PABH with those of EPB and DClEPB addi-
tionally underlines the importance of the pyridyl nitrogen
for receptor activation. Obviously, the nitrogen as a hydro-
gen-bond acceptor is essential in the structures of EPB
and DClEPB to make them strong agonists.
Electrophysiological data obtained with 4PABH revealed
no major differences versus PABH. In contrast to an ortho
nitrogen as in 2PABH, a para nitrogen seems to have no
impact on activation of the receptors. Compared to
DClEPB and EPB the pyridine nitrogen of 2PABH and
4PABH is moved 60° towards or away from the azabicyclo
moiety. As a result, the nitrogen orbitals with the free
electron pair are pointing in different directions. The data
show that the spatial orientation of the para nitrogen,
which has a nonflexible N–N distance hardly longer than
EPB, does not allow an interaction with the receptor.
HEPB is EPB enlarged in the azabicyclo ring by one
CH2 unit. The differences of HEPB compared to EPB
were remarkable. Although the efficacy of (+)-HEPB was
similar to that of EPB, (–)-HEPB displayed a distinct loss
of activity. Obviously, this structural variation induced a
strong enantioselectivity. Recently published results have
described a similar phenomenon with another modification
of EPB. By attaching a methyl group to the 7-aza-position
of EPB a reduced effectivity of the (+)-enantiomer was
observed [22].
In conclusion, non-natural derivatives of EPB make it pos-
sible to investigate the structure–activity relationship of a
rather simple ligand in its interaction with the neuronal
nicotinic acetylcholine receptor. Small changes in the mol-
ecular structure produce marked changes in its capacity to
activate or inhibit nAChR subtypes. Subtype specificity
can be achieved by changing the N–N distance, by chang-
ing the orientation of the free electrons of the pyridyl
nitrogen and/or by changes in the azabicyclo ring.
Significance
Epibatidine is an agonist towards the neuronal nicotinic
acetylcholine receptor (nAChR) with both optical
isomers equally effective, as determined by voltage
clamp electrophysiology.
Small structural changes induce enantiomeric speci-
ficity, subtype specificity and dramatic changes in the
effectivity to elicit a functional response. Removal of the
pyridyl chlorine reduces the efficiency towards the α4β2
subtype and more so for the (–)-enantiomer. The change
towards the ganglionic α3β4 subtype is smaller and more
pronounced for the (+)-enantiomer. Virtually no change
is observed towards the homomeric α7 subtype. Putting
the pyridyl nitrogen in the ortho position with respect to
the aza-bicyclo-ring reduces the efficiency towards α4β2
and α3β4 even further and the (–)-enantiomer is an
agonist towards α7. Putting the pyridyl nitrogen in the
para position and elimination of the pyridyl nitrogen
direct the efficacy towards the α3β4 subtype. Extension
of the aza-bicyclo-ring induces enantioselectivity, result-
ing in a 50-fold higher efficiency for one enantiomer.
A nAChR ligand contains a positively charged quater-
nary ammonia nitrogen and a part that interacts with
the receptor by hydrogen bonding and pi-interaction. The
biological activity can be described as different stabilisa-
tion of the open activated or of the closed desensitised or
closed resting state of the receptor by the various
ligands.
Materials and methods
Chemistry
Syntheses and analysis
Unless otherwise stated reagents were obtained in analytical grade
from commercial sources (Aldrich, Fluka, Merck, Sigma). NMR spectra
were obtained on a VARIAN Gemini 300 spectrometer using tetram-
ethylsilane as an internal standard. Mass spectra were recorded on a
Trio 2000 spectrometer (VG ORGANIC, UK) using electrospray in
positive ion mode (ES+). The optical purity is reported in % of enan-
tiomeric excess (% ee).
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The key step in the preparation of all ligands presented herein is the
Heck reaction (see Figure 1). By using this highly flexible C–C-coupling
synthesis, modifications in the EPB structure were easily accessible.
Detailed preparations of EPB [60], HEPB [61], DClEPB [62] and
2PABH [24] were recently reported. For synthesis of 4PABH,
N-methoxycarbonyl-7-azabicyclo[2.2.1]heptene (330 mg, 2.15 mmol),
prepared according to Clayton et al. [60], was dissolved with 4-bromo-
pyridine (849 mg, 5.38 mmol, 2.5 eq.), tetrakis(triphenyl-phosphine)pal-
ladium (124 mg, 0.11 mmol, 5 mol%), in dry N,N-dimethylformamide
(3 ml), piperidine (549 mg, 6.45 mmol, 3 eq.) and formic acid (300 mg,
6.45 mmol, 3 eq.). After stirring (6.5 h, 80°C) under argon, water was
added (15 ml). Ether extracts (4 × 25 ml) were washed with water, dried
(sodium sulphate) and evaporated to give an oil (310 g), which was
purified by flash chromatography (ethylacetate) to give N-methoxycar-
bonyl-4PABH (210 mg, 42%). 1H NMR (300 MHz, CDCl3): δ 8.48 (dd,
J = 4.4, 1.6 Hz, 2H), 7.22 (dd, J = 4.4, 1.6, 2H), 4.35–4.25 (m, 2H),
3.64 (s, 3H), 2.84 (dd, J = 5.0, 8.7 Hz, 1H), 2.0–1.6 (m, 6H) ppm; 13C
NMR (300 MHz, CDCl3): δ 156.7, 153.9, 149.8, 122.3, 61.4, 56.5,
52.4, 47.3, 39.7, 30.9, 28.8 ppm; mass spectrum (electro spray, cone
voltage +40 V) m/z 233 [M+1]+. 
The methyl carbamate (170 mg, 0.73 mmol) was dissolved in 33%
hydrogen bromide in acetic acid (3.0 ml) and stirred at room tempera-
ture for 17 h. Water was added and the solution made basic with 40%
aqueous NaOH. The mixture was extracted with dichloromethane
(3 × 10 ml), dried (sodium sulfate) and evaporated to give an oil, which
was purified by flash chromatography (ethylacetate/triethylamine,
90/10, v/v) to give 4PABH (81 mg, 0.46 mmol, 64%). 1H NMR
(200 MHz, CDCl3): δ 8.47 (dd, J = 4.7, 1.6 Hz, 2H), 7.14 (dd, J = 4.7,
1.6, 2H), 3.81–3.65 (m, 2H), 2.79 (dd, J = 5.0, 8.7 Hz, 1H), 2.35 (br s,
1H), 2.0–1.5 (m, 6H) ppm; 13C NMR (300 MHz, CDCl3): δ 155.0,
149.5, 122.4, 62.1, 56.3, 47.1, 39.5, 30.9, 29.6 ppm; mass spectrum
(electro spray, cone voltage +40 V) m/z 175 [M+1]+.
By analogy to the procedure presented above the heptene (70 mg,
0.46 mmol) was reacted with iodobenzene (235 mg, 1.15 mmol) to
obtain N-methoxycarbonyl-PABH (0.20 mmol, 47 mg, 44%). 1H NMR
(200 MHz, CDCl3): δ 7.37–7.14 (m, 5H), 4.45 (br s, 1H), 3.30 (br s,
1H), 3.65 (s, 3H), 2.89 (dd, J = 8.4, 5.5 Hz, 1H), 2.0–1.5 (m, 6H) ppm;
13C NMR (300 MHz, CDCl3): δ 145.6, 129.5, 128.5, 127.2, 126.2,
62.1, 56.1, , 52.2, 48.1, 40.1, 29.9, 28.8 ppm; mass spectrum (electro
spray, cone voltage +40 V) m/z 232 [M+1]+.
Deprotection of the carbamate (41 mg, 0.18 mmol) in a similar way as
described above, yielded PABH (17.4 mg, 0.10 mmol, 56%). 1H NMR
(200 MHz, CDCl3): δ 7.30–7.16 (m, 5H), 3.77 (dd, J = 4.2, 4.2 Hz, 1H),
3.65 (d, J = 4.1 Hz, 1H), 2.88 (dd, J = 8.8, 5.2 Hz, 1H), 1.92 (dd,
J = 12.4, 8.9 Hz 1H), 1.8–1.3(m, 5H) ppm; 13C NMR (300 MHz, CDCl3):
δ 146.6, 128.5, 127.2, 125.9, 62.9, 56.5, 48.0, 40.1, 30.8, 29.7 ppm;
mass spectrum (electro spray, cone voltage +40 V) m/z 174 [M+1]+.
Separation of the enantiomers
All enantiomers were separated on a chiral ChirobioticT column in
analogy to the procedures described recently [24,34,63]. Optical
purity of enantiomers was checked with the same HPLC set-up as
used for the semipreparative separations. The stereoisomers of EPB,
HEPB as well as of DClEPB eluted in high optical purity (> 99.8% ee).
Enantiomeric (–)-2PABH and (+)-2PABH were obtained in optical
purity of > 99.8% ee and > 98.0% ee, respectively.
Electrophysiology
All the cDNA constructions were cloned from rat. For the α7, α3β4 and
α4β2 nAChRs reconstitution in Xenopus oocytes vector pcDNAIneo
with RSV promoter was used. Oocytes were harvested from female
Xenopus leavis, prepared and injected as previously described
[64,65]. Oocytes were injected with rat cDNA combinations α4β2,
α3β4 and α7 and the physiological properties of the different subtypes
were examined 2–3 days following the injection using a dual-electrode
voltage clamp. Electrophysiological recordings were performed using a
dual-electrode voltage clamp apparatus (Geneclamp, Axon Instru-
ments, Forster City, CA) [65]. During the experiments, oocytes were
continuously superfused with control solution containing 82.5 mM
NaCl, 2.5 mM KCl, 5 mM HEPES, 2.5 mM CaCl2, 1 mM MgCl2, pH 7.4
(NaOH). Perfusion was gravity fed at roughly 6 ml/min and drugs were
applied by electromagnetic valves (general valve type III) controlled by
computer. Unless indicated, cells were held throughout the experi-
ments at –100 mV. Data are represented with their respective standard
error of mean (SEM).
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